Abstract
Aim: The current study observed the antidiabetic effect of Vasant Kusumakar Ras, an Ayurvedic polyherbal formulation, in alloxan-induced and dexamethasone-induced diabetic rats.
Materials and Methods: Alloxan (120 mg/kg, i.p.) and dexamethasone sodium phosphate (5 mg/kg, i.p.) were used to induce diabetes in rats. The oral antidiabetic activity of Vasant Kusumakar Ras was evaluated by single doses of Vasant Kusumakar Ras (400 and 600 mg/kg, p.o.) in albino rats during a 10-day treatment period, with the effect of the Vasant Kusumakar Ras on blood glucose levels and serum lipid parameters measured on 0, 7th, and 11th day. Glibenclamide (5 mg/kg, p.o.) was used as the reference drug.
Results: In alloxan-induced diabetic rats, the elevated levels of blood glucose significantly (p < 0.05) decreased after oral administration of Vasant Kusumakar Ras (400 mg/kg and 600 mg/kg), and Glibenclamide (5 mg/kg). When compared to the diabetic control group, treatment with Vasant Kusumakar Ras and Glibenclamide for 10 days reduced total cholesterol (TC) significantly (p < 0.001). Treatment with Vasant Kusumakar Ras and Glibenclamide for 10 days, significantly (p < 0.001) decreased low-density lipoprotein (LDL) level when compared to the diabetic control group. In dexamethasone-induced diabetic rats, all rats given with dexamethasone and Vasant Kusumakar Ras (400 mg/kg and 600 mg/kg) showed a significant (p < 0.05) decrease in the level of blood glucose when compared with diabetic control rats. The rats treated with dexamethasone and Glibenclamide showed a significant (p < 0.05) decrease in blood glucose level when compared to diabetic control rats. When compared to the diabetic control group, treatment with Vasant Kusumakar Ras and Glibenclamide (5 mg/kg) for 10 days reduced TC significantly (p < 0.001). Treatment with Vasant Kusumakar Ras and Glibenclamide for 10 days, significantly (p < 0.001) decreased LDL level when compared to the diabetic control group.
Conclusion: Vasant Kusumakar Ras was shown to have significant antidiabetic activity comparable to that of glibenclamide and it also improves the lipid metabolism in both alloxaninduced and dexamethasone-induced diabetic rats.